Predictors of Clinical Success Among a National Veterans Affairs Cohort With Methicillin-Resistant Staphylococcus aureus Pneumonia by Caffrey, Aisling R et al.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2014
Predictors of Clinical Success Among a National
Veterans Affairs Cohort With Methicillin-Resistant
Staphylococcus aureus Pneumonia
Aisling R. Caffrey
University of Rhode Island, aisling_caffrey@uri.edu
Haley J. Morrill
University of Rhode Island
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Caffrey, A. R., Morrill, H. J., Puzniak, L. A., & LaPlante, K. L. (2014). Predictors of clinical success among a national veterans affairs
cohort with methicillin-resistant Staphylococcus aureus pneumonia. Clinical Therapeutics, 35(4), 552-559. doi: 10.1016/
j.clinthera.2014.02.013
Available at: http://dx.doi.org/10.1016/j.clinthera.2014.02.013
Authors
Aisling R. Caffrey, Haley J. Morrill, Laura A. Puzniak, and Kerry L. LaPlante
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/31
1 
 
Predictors of Clinical Success Among a National Veterans Affairs Cohort with Methicillin-
Resistant Staphylococcus aureus Pneumonia 
 
Aisling R. Caffrey, PhD, MS1,2; Haley J. Morrill, PharmD1,2; Laura A. Puzniak, PhD, MPH3; and 
Kerry L. LaPlante, PharmD1,2,4 
 
1Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode 
Island; 2University of Rhode Island, College of Pharmacy, Kingston, Rhode Island; 3Pfizer Inc, 
Collegeville, Pennsylvania; 4Warren Alpert Medical School of Brown University, Division of 
Infectious Diseases, Providence, Rhode Island 
 
Address correspondence to: Kerry L. LaPlante, PharmD, Veterans Affairs Medical Center 
(151), Research Building 35, 830 Chalkstone Avenue, Providence, RI 02908. Tel: 401-273-7100 
x2339; Fax: 401-457-3305. E-mail: KerryLaPlante@uri.edu 
 
Running head: Predictors of MRSA Pneumonia Treatment Success  
 
An earlier version of this research was presented at the 52nd Interscience Conference on 
Antimicrobial Agents and Chemotherapy, September 9–12, 2012, San Francisco, California.  
  
2 
 
ABSTRACT  
 Background: The treatment of methicillin-resistant Staphylococcus aureus (MRSA) 
pneumonia is exceedingly complicated, which is concerning because of the high mortality rate 
associated with the infection. Identification of independent predictors of clinical success can 
optimize patient care by assisting clinicians in treatment decisions. 
 Objectives: We sought to identify independent predictors of clinical success in a 
national Veterans Affairs (VA) cohort of MRSA pneumonia patients. 
 Methods: A nested case-control study was conducted among a cohort of VA patients 
with MRSA pneumonia receiving linezolid or vancomycin between January 2002 and 
September 2010. Cases included those demonstrating clinical success, defined as discharge 
from the hospital or intensive care unit (ICU) by day 14 after treatment initiation, in the absence 
of death, therapy change, or intubation by day 14. Controls represented non-success, defined 
as therapy change, intubation, ICU admission, re-admission, or death between treatment 
initiation and day 14. The potential predictors assessed included treatment, patient 
demographics and admission characteristics, previous healthcare and medication exposures, 
comorbidities, and medical history. Odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated from logistic regression. 
 Results: Our study included 2442 cases of clinical success and 1290 controls. 
Demographics varied between the clinical success and non-success groups, including age, 
race, and region of facility. A current diagnosis of chronic respiratory disease (46% vs 42%) and 
diagnosis of pneumonia in the year prior to the MRSA pneumonia admission (37% vs 32%) 
were both more common in the clinical success group. Despite these significant differences, 
only two predictors of clinical success were identified in our study: previous complication of an 
implant or graft, including mechanical complications and infections, in the year prior to the 
MRSA pneumonia admission (OR, 1.55; 95% CI, 1.17–2.06) and treatment with linezolid (1.53; 
1.12–2.10). Predictors of non-success included concomitant urinary tract infection diagnosis 
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(OR, 0.82; 95% CI, 0.70–0.96), intravenous line (0.76; 0.66–0.89), previous coagulopathy (0.74; 
0.56–0.96), previous amputation procedure (0.72; 0.53–0.98), current coagulopathy diagnosis 
(0.71; 0.53–0.96), dialysis (0.54; 0.38–0.76), multiple inpatient procedures (0.53; 0.45–0.62), 
inpatient surgery (0.48; 0.41–0.57), and previous endocarditis (0.24; 0.07–0.81).  
Discussion: MRSA pneumonia tends to affect complex patients, and identification of the 
predictors of clinical success is useful when considering different therapeutic approaches. 
 Conclusions: In a national cohort of VA patients with MRSA pneumonia, treatment was 
the only modifiable variable predicting clinical success.  
 
Key words: predictors of clinical success, linezolid, vancomycin, methicillin-resistant 
Staphylococcus aureus, pneumonia. 
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INTRODUCTION 
Pneumonia is the leading cause of infectious disease-related deaths in the United States.1 A 
prominent pathogen causing pneumonia in both healthcare and community settings is 
methicillin-resistant Staphylococcus aureus (MRSA).2 In recent years, rates of community-
associated MRSA pneumonia have been steadily increasing, while MRSA was also becoming a 
leading cause of healthcare-associated pneumonia, including ventilator-associated pneumonia 
(VAP).3,4 
Limited options exist for the treatment of MRSA pneumonia. Vancomycin has been the 
mainstay of treatment for MRSA infections for years, however rates of treatment failure for 
pneumonia as high as 40% have been reported.5 Linezolid is a well-studied alternative to 
vancomycin that has been available for more than 10 years. Several studies have demonstrated 
clinical equivalence between the 2 drugs,6-9 but some data suggest a significant benefit for 
linezolid compared with vancomycin for the treatment of pneumonia.10-12 Currently, both drugs 
are recommended as first-line options for the treatment of MRSA pneumonia.2  
In addition to treatment-related factors, host and pathogen characteristics can affect 
clinical outcomes for patients with MRSA pneumonia. For example, age, underlying 
comorbidities, severity of illness, multiple lobe involvement, and need for intensive care unit 
(ICU) admission have been associated with poor clinical outcomes.9-11,13,14 There are multiple 
differences among MRSA strains on a molecular level, including staphylococcal cassette 
chromosome mec (SCCmec) type, presence of the toxin Panton-Valentine leukocidin, and 
minimum inhibitory concentration, which can affect clinical outcomes.14-16 
MRSA pneumonia is a complex disease associated with significant morbidity and 
mortality. Despite the large public health impact of MRSA pneumonia, there are limited 
published data examining clinical predictors of success or failure. Identification of independent 
predictors of clinical success could optimize patient care by assisting clinicians in treatment 
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decisions. It was therefore the aim of this study to identify independent predictors of clinical 
success among a national Veterans Affairs (VA) cohort of MRSA pneumonia patients.  
 
METHODS 
The study design and methods were defined a priori in the study protocol, which was reviewed 
and approved by the Institutional Review Board and Research and Development Committee of 
the Providence Veterans Affairs Medical Center.  
 
Data Sources  
 The Veterans Health Administration has utilized an electronic medical record system 
since 1999. Our study included national standardized databases capturing patient care: 
International Classification of Diseases, 9th Revision (ICD-9) diagnostic and procedure codes, 
pharmacy records for prescriptions, laboratory tests, select laboratory results, mortality, and 
patient vital signs.17,18  
 
Patient Population and Study Design 
 Our nested case-control study was conducted among an original cohort of patients 
admitted to VA hospitals between January 1, 2002, and September 30, 2010, with an ICD-9 
code for MRSA (038.12, 041.12, 482.42, V09.0) and pneumonia (482.40-482.42, 482.49, 
482.89, 482.9, 484.8, 485-486, 510.0, 510.9, 513.0-513.1).19 Patients aged 18 years or older 
were selected for inclusion if they were initiated on linezolid or vancomycin during the 
admission, in the absence of linezolid or vancomycin therapy in the 7 days prior to the 
hospitalization, with at least 3 days of therapy dosed per hospital protocol. Patients were 
excluded if they died or were discharged within 3 days of treatment initiation, were initiated on 
vancomycin or linezolid in the nursing home before their hospital admission, or were exposed to 
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more than 2 consecutive days of anti-MRSA antibiotics in the 3 days before treatment initiation 
or during treatment with linezolid or vancomycin. Only the first admission within the study period 
meeting all inclusion and exclusion criteria was included.  
To identify independent predictors of clinical success among our MRSA pneumonia 
cohort, we identified cases of clinical success and a non-success control group. Clinical success 
was defined as discharge from the hospital and/or from the ICU by day 14 after treatment 
initiation, in the absence of therapy change, intubation, admission to the ICU, re-admission, 
and/or death by day 14.19 Non-success was defined as therapy change, intubation, ICU 
admission, discharge and readmission, or death between treatment initiation and day 14.19 Day 
14 was chosen to replicate the average end-of-treatment time frame from existing linezolid and 
vancomycin clinical trials.6,7,12 Our definition of clinical success was defined a priori based on 
recently published clinical trials utilizing clinical outcomes available from our data source.6,7,12 
 
Independent Predictors 
 The potential predictors assessed included treatment (linezolid or vancomycin), patient 
demographics and admission characteristics, comorbidities and medical history, vital signs and 
laboratory results, previous surgeries and procedures, previous healthcare exposures, and 
previous medication exposures.19 To identify comorbidities and medical history, including site-
specific and organism-specific infections in the year before admission, ICD-9 diagnosis and 
procedure codes from inpatient and outpatient records were utilized.18 Surgeries, procedures, 
and radiologic examinations during the admission were identified using ICD-9 diagnosis and 
procedure codes. Hospital admissions, surgeries, and nursing home or extended-care stays 
were evaluated from 5 non-mutually exclusive time periods (30 days, 60 days, 90 days, 180 
days, 365 days) to identify previous healthcare exposures. Previous antibiotic and 
immunosuppressant exposures during the 90 days before admission were identified from 
inpatient and outpatient prescription records. 
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Statistical Analysis 
 Between-group differences were assessed using a χ2 or Fisher’s exact test for 
categorical covariates and the t-test or Wilcoxon rank-sum test for continuous variables, as 
appropriate. An unconditional logistic regression model was developed to identify independent 
predictors associated with clinical success using a manual backward, non–computer-generated, 
elimination approach.20 We report unadjusted and multivariable adjusted odds ratios (ORs) for 
each predictor, including their respective 95% confidence intervals (CIs). All analyses were 
performed using SAS (SAS Institute Inc., Cary, NC, Version 9.1.3). 
 
RESULTS 
Our study included 2442 cases of clinical success and 1290 non-success controls. There were 
significant differences in demographics between the clinical success and non-success groups, 
including age and race (Table I). Patients in the clinical success group were older than patients 
in the non-success group (mean age 69.5 ± 12.6 years vs 68.5 ± 12.0 years, P < 0.05). White 
patients made up a larger proportion of the clinical success group than the non-success group 
(81.7% vs 79.1%, P < 0.05). Several significant differences in comorbidities were also observed 
between groups, including less frequent peripheral vascular disease, coagulopathy, and dialysis 
and more frequent chronic respiratory disease among patients experiencing clinical success. In 
addition, patients with clinical success were less likely to have an intravenous line or current 
complication of an implant or graft and were less likely to be in a surgical unit at treatment 
initiation.  
Treatment with linezolid was more common in the clinical success group (6.8% vs 5.0%, 
P < 0.05), as shown in Table II. Other differences between cases and controls included shorter 
length of therapy and a larger proportion of subjects with pneumonia infections or previous 
implant or graft in the last year among those with clinical success. 
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 Statistically significant predictors of clinical success, as compared with non-success, are 
shown in Table III. In the adjusted logistic regression model, 2 independent predictors of clinical 
success were identified: previous complication of an implant or graft, including mechanical 
complications and infections, in the year prior to the MRSA pneumonia-related admission 
(adjusted OR, 1.55; 95% CI, 1.17–2.06) and treatment with linezolid (1.53; 1.12–2.10). 
Predictors with Odds Ratios <1, and as such associated with non-success, included 
concomitant urinary tract infection diagnosis (adjusted OR, 0.82; 95% CI, 0.70–0.96), 
intravenous line during the current MRSA pneumonia admission (0.76; 0.66–0.89), 
coagulopathy in the year prior to the MRSA pneumonia admission (0.74; 0.56–0.96), previous 
amputation procedure (0.72; 0.53–0.98), current coagulopathy diagnosis (0.71; 0.53–0.96), 
current dialysis (0.54; 0.38–0.76), 3 or more inpatient procedures (0.53; 0.45–0.62) or inpatient 
surgery (0.48; 0.41–0.57) during the current MRSA pneumonia admission, and previous 
endocarditis (0.24; 0.07–0.81).  
 
DISCUSSION 
In our study, the only modifiable variable predicting clinical success among patients with MRSA 
pneumonia was linezolid treatment. Clinical success was 1.53 times more likely among patients 
treated with linezolid compared with those treated with vancomycin. Two earlier retrospective post 
hoc studies demonstrated, in subgroup analyses, that treatment with linezolid (vs vancomycin) 
was an independent predictor of clinical cure for MRSA pneumonia (OR, 3.3; 95% CI, 1.3–8.3, 
P = 0.01) and MRSA VAP (OR, 20.0; 95% CI, 4.3–92.0, P < 0.001).10,11 Limitations of these 
studies include their post hoc design, subgroup analyses, and lack of vancomycin dose 
optimization.  
 Several studies have evaluated the comparative clinical efficacy of linezolid and 
vancomycin with conflicting results. In contrast to our findings, numerous randomized trials have 
demonstrated no difference in clinical cure rates for the treatment of nosocomial pneumonia 
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when comparing linezolid and vancomycin.6-9,21 Moreover, in 2 meta-analyses, linezolid 
treatment for nosocomial pneumonia was not associated with clinical superiority over 
glycopeptides (vancomycin or teicoplanin).22,23  
The few trials that support our finding of more frequent clinical success associated with 
linezolid treatment have been criticized for methodological and statistical flaws.11,12,24-31 One of 
these studies, a recent randomized controlled trial, demonstrated higher clinical success 
associated with linezolid versus vancomycin in the treatment of MRSA pneumonia.12 In this 
study, 57.6% (95/165) of linezolid patients and 46.6% (81/174) of vancomycin patients achieved 
clinical success (95% CI for the difference, 0.5%–21.6%, P = 0.042). However, questions 
regarding vancomycin dose optimization remain, since median trough levels of vancomycin fell 
below the Infectious Diseases Society of America’s recommendations in that trial.2 Several 
retrospective studies have developed algorithms to evaluate clinical success or failure related to 
MRSA pneumonia.32-34 Our study further adds to this developing literature by assessing a large 
national cohort of patient with MRSA pneumonia using objective clinical outcomes. 
It is unclear why a previous complication of an implant or graft was associated with 
clinical success in our study. Complications included a range of conditions, such as mechanical 
complications, infections, or other non-specified complications of medical devices, implants, or 
grafts.18 One possible explanation is that this specific medical history could have prompted more 
aggressive measures to improve the likelihood of clinical success. If this were the case, our 
findings suggest that MRSA pneumonia patients with previous endocarditis, coagulopathy, and 
amputation procedures in the year prior to admission may also benefit from additional efforts to 
improve clinical success. 
There are multiple limitations to our study. First, it should be noted that our definition of 
clinical success varies from those of the aforementioned clinical trials, which affects our ability to 
make direct comparisons. However, our definition was determined by objective criteria of clinical 
outcomes rather than clinical judgment as used in those trials. Other limitations include our 
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retrospective design and use of diagnosis codes to identify MRSA pneumonia. There may be 
variations in coding practices across institutions, and the MRSA coding can be discordant with 
culture-confirmed MRSA.35 Furthermore, we were unable to molecularly classify the MRSA 
isolates; molecular differences in MRSA strains have been shown to affect clinical results.14-16 
Susceptibility data and trough data were not available, and therefore it is not known if subjects 
reached therapeutic levels of the treatment agent.  
In summary, clinical success in our study was 53% higher among MRSA pneumonia 
patients treated with linezolid compared with those treated with vancomycin. Previous 
complication of an implant or graft in the year prior to the MRSA pneumonia-related admission 
was also a predictor of clinical success. In addition, concomitant urinary tract infection, 
intravenous line, previous coagulopathy, previous amputation procedure, current coagulopathy, 
dialysis, 3 or more inpatient procedures, inpatient surgery, and previous endocarditis were 
associated with lower odds of clinical success. This study helps to identify patients who may 
have additional complexities owing to comorbid conditions or medical history and who may 
benefit from alterations in treatment regimen or require additional attention. Treatment was the 
only modifiable predictor of clinical success in our study. These findings, based on existing 
national health data, support the results of previous studies and can assist clinicians in 
managing patients with MRSA pneumonia. 
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Table I. Demographics, hospitalization-related characteristics, and comorbidities by 
clinical success.  
Potential Predictors 
Clinical Success 
(n = 2442) 
Clinical Non-success 
(n = 1290) 
Age (years), mean (SD)* 69.5 (12.6) 68.5 (12.0) 
Male gender, n (%) 2401 (98.3) 1263 (97.9) 
Race, n (%)*   
White 1996 (81.7) 1021 (79.1) 
Other/unknown 446 (18.3) 269 (20.9) 
Admission source   
Home 919 (37.6) 462  (35.8) 
Emergency room 1071 (43.9) 588 (45.6) 
Hospital 150 (6.1) 83 (6.4) 
Nursing home 302 (12.4) 157 (12.2) 
Unit at treatment initiation*   
Intensive care 1042 (42.7) 544 (42.2) 
Surgery 121 (5.0) 91 (7.1) 
General medicine 1279 (52.4) 655 (50.8) 
Treating specialty   
Intensive care 953 (39.0) 519 (40.2) 
Surgery 78 (3.2) 54 (4.2) 
General medicine 1411 (57.8) 717 (55.6) 
Region of facility*   
North 320 (13.1) 169 (13.1) 
South 1056 (43.2) 620 (48.1) 
Midwest 512 (21.0) 243 (18.8) 
West  554 (22.7) 258 (20.0) 
Charlson comorbidity index, median 
(IQR)* 2 (1-4) 2 (1-4) 
Comorbid conditions, n (%)   
Chronic respiratory disease* 1123 (46.0) 536 (41.6) 
Renal disease 364 (14.9) 219 (17.0) 
     Dialysis* 68 (2.8) 87 (6.7) 
Diabetes 778 (31.9) 419 (32.5) 
Heart failure 608 (24.9) 334 (25.9) 
Coronary heart disease 596 (24.4) 296 (22.9) 
Cancer 430 (17.6) 247 (19.1) 
   
Amputation* 59 (2.4) 51 (4.0) 
Cerebrovascular disease 215 (8.8) 123 (9.5) 
Peripheral vascular disease* 148 (6.1) 111 (8.6) 
Moderate or severe liver disease 43 (1.8) 30 (2.3) 
HIV/AIDS 25 (1.0) 16 (1.2) 
Coagulopathy* 109 (4.5) 93 (7.2) 
Peripheral line* 804 (32.9) 622 (48.2) 
Complication of implant or graft* 153 (6.3) 127 (9.8) 
Urinary tract infection* 616 (25.2) 377 (29.2) 
Bacteremia  475 (19.5) 263 (20.4) 
Skin infection 560 (22.9) 323 (25.0) 
18 
 
SD = standard deviation; IQR = interquartile range; MRSA = methicillin-resistant 
Staphylococcus aureus. 
*P < 0.05. 
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Table II. Previous infections, healthcare and medication exposures by clinical success. 
 
Potential Predictors 
Clinical Success 
(n = 2442), n (%) 
Clinical Non-success 
(n = 1290), n (%) 
Treatment*   
Linezolid 167 (6.8) 64 (5.0) 
Vancomycin 2275 (93.2) 1226 (95.0) 
Length of therapy, days, median (IQR)* 7 (5-10) 6 (4-12) 
Previous hospitalization last year 1682 (68.9) 866 (67.1) 
Previous hospitalization last 90 days 1256 (51.4) 655 (50.8) 
Previous hospitalization last 30 days 929 (38.0) 497 (38.5) 
Previous surgery last year 496 (20.3) 277 (21.5) 
Previous surgery last 90 days 256 (10.5) 146 (11.3) 
Previous surgery last 30 days 117 (4.8) 72 (5.6) 
Previous procedure last year 1468 (60.1) 778 (60.3) 
Previous procedure last 90 days 983 (40.3) 539 (41.8) 
Previous procedure last 30 days 608 (24.9) 350 (27.1) 
Previous anti-MRSA antibiotics last 90 
days 1108 (45.4) 563 (43.6) 
Previous immunosuppressants last 90 
days 
Previous corticosteroids last 90 days 
60 (2.5) 
631 (25.8) 
39 (3.0) 
311 (24.1) 
Previous infections last year   
Pneumonia*† 910 (37.3) 418 (32.4) 
Skin or subcutaneous tissue infection† 720 (29.5) 403 (31.2) 
Bacteremia† 159 (6.5) 77 (6.0) 
Urinary tract infection† 592 (24.2) 302 (23.4) 
Osteomyelitis† 86 (3.5) 58 (4.5) 
MRSA 290 (11.9) 160 (12.4) 
Pseudomonas aeruginosa 120 (4.9) 58 (4.5) 
Previous complication of implant or graft 
last year* 205 (8.4) 81 (6.3) 
IQR = interquartile range; MRSA = methicillin-resistant Staphylococcus aureus. 
*P < 0.05.  
†Attributed to any organism. 
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Table III. Independent predictors of clinical success. 
 
Predictors 
Unadjusted Odds Ratio  
(95% Confidence Interval) 
Adjusted Odds Ratio  
(95% Confidence Interval) 
Previous complication 
of an implant or graft 1.37 (1.05–1.79) 1.55 (1.17–2.06) 
Treatment (linezolid vs 
vancomycin) 1.41 (1.05–1.89) 1.53 (1.12–2.10) 
  
 
Urinary tract infection 0.82 (0.70–0.95) 0.82 (0.70–0.96) 
Peripheral line 0.53 (0.46–0.61) 0.76 (0.66–0.89) 
Previous coagulopathy 0.72 (0.56–0.92) 0.74 (0.56–0.96) 
Previous amputation 
procedure 0.71 (0.53–0.94) 0.72 (0.53–0.98) 
Coagulopathy 0.60 (0.45–0.80) 0.71 (0.53–0.96) 
  
 
Dialysis 0.40 (0.29–0.55) 0.54 (0.38–0.76) 
Inpatient procedures, 
3 or more 0.40 (0.35–0.46) 0.53 (0.45–0.62) 
Inpatient surgery 0.38 (0.33–0.45) 0.48 (0.41–0.57) 
Previous endocarditis 0.23 (0.07–0.76) 0.24 (0.07–0.81) 
 
